Cached score snapshot

US.PODD · Insulet Corporation

110分制 60.5/110;5D動能v2 6/50;排序分 66.5/160 · Incomplete inputs

Ranking score 66.5/160
Main score 60.5/110
5D momentum v2 6/50
Rank #181
Setup grade F 33.2

Score breakdown

觀望

Elevated twelvedata

Score and price trend

F 33.2 Technical A · Elevated risk

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-07 08-03 08-18 09-01 09-14 $132.39$178.82$225.25 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.484 · anchors 120 -0.40% -1.83% / +2.07% 40% 2.5% Actual -17.91% · vs median -17.51% · inside 25-75 band
30D observation +9.50% +6.15% / +18.38% 90% 0% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 -0.53% -2.12% / +1.81% 42.5% 5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-05-07 → 2026-09-14 · 235 archived points · 1 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 66.5
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 60.5/110 (觀望)
5D momentum v2 6/50 (弱)
Score with momentum v2 66.5/160 (低排序)
Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 163.1505
ma50 155.5868
close 169.7
prevClose 165.35
avgVolume20 1271450
volumeRatio 1.11
changePercent 2.63

Metrics snapshot

close 169.7
volume 1408003
changePercent 2.63

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 60.5/110
Main rating 觀望
5D momentum v2 6/50
Score with momentum v2 66.5/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.2/5 · 一般

Dimension score 3.2/5
Dimension grade 一般

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.75
debtPoints 0.4
marginPoints 0
turnoverUsdM 238.9381
volumePoints 0.5
revenuePoints 0.75
dividendPoints 0
marketCapPoints 0.4

資金流 — 13.2/20 · 一般

Dimension score 13.2/20
Dimension grade 一般

Sub-items

cmfPoints 1.6
mfiPoints 3.2
obvPoints 2.4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.PODD
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 5.8/15 · 較差

Dimension score 5.8/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 3

details

qqq

ma20 699.881
ma50 714.8264
name QQQ
close 700.07
points 1

spy

ma20 746.014
ma50 745.3184
name SPY
close 757.67
points 2
source twelvedata+fred
atrPct 3.9504
atrPoints 2
cciPoints 0.8
vixPoints 0
marketTrendPoints 3

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 7
catalystCount 0
catalystPoints 2

風險管理 — 6.1/10 · 一般

Dimension score 6.1/10
Dimension grade 一般

Sub-items

position

score 1.1

details

atrPct 3.9504
turnoverUsdM 238.9381
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.8

stopLevels

symbol US.PODD
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 156.2922

strength_details

ma_score 1.5
atr_score 1
rsi_score 3
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.6
stop_loss_percent 7.9
take_profit_price 191.3313
target_multiplier 2.2
technical_strength 2.2
take_profit_percent 12.7
positionPoints 1.1
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.6074
stopLossPercent 7.9009
diversificationPoints 2

技術信號 — 24.2/30 · 優秀

Dimension score 24.2/30
Dimension grade 優秀

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 2.2
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 2.2
vcp_reason 波幅收縮(20.1%→9.1%);跌縮量(近10日5日);站上MA50;Ready=Y;Confirm=N

vcp_metrics

up_days 4
vol_ref 1455786.6667
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 1252980
avg_vol_20 1269585
avg_vol_30 1455786.6667
range_pct_10 0.0912
range_pct_20 0.1187
range_pct_30 0.2011
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 0
breakout_20d_ok false
vol_ratio_10_30 0.8607
dist_to_20d_high 0.0186
down_shrink_days 5
breakout_level_20d 172.92
vcp_breakout_confirm false
contraction_ratio_10_30 0.4536
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.8
rsiKdjPoints 4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 1.2

情緒分析 — 6/10 · 一般

Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 7
negativeHits 0
positiveHits 5
sentimentScoreRaw 1.7

sentimentData

raw {"id":140917722,"url":"https://finnhub.io/api/news?id=e46a532cdcf0dfbb64292f767f3f6794a84ac828a31a539cbc29825883436c13","image":"https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp","source":"ChartMill","related":"PODD","summary":"Insulet Corp (PODD) fits the Affordable Growth strategy with strong earnings and revenue momentum, neutral valuation, and high profitability—offering compound growth potential without overpaying for the stock.","category":"company","datetime":1784190635,"headline":"Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum"}, {"id":140886060,"url":"https://finnhub.io/api/news?id=f420465558bfb0230f65b0aa19dc7f11d45f18388c9c4b1a6a92b970aba5542a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]","category":"company","datetime":1783950597,"headline":"Insulet Corporation (PODD) Fell Along with Broad Medtech Sector"}, {"id":140859201,"url":"https://finnhub.io/api/news?id=414b0a5634543092ba8bf64f081fcb337e447dd1b8872829ff817b395e428636","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet stock has fallen sharply over the past year, yet the valuation checks still lean toward the shares being on the expensive side rather than a clear bargain. Insulet is down 46.8% over the past year, which means anyone looking at the stock today is doing so after a significant reset in the share price. On the one hand, growth expectations around the Omnipod franchise may support the current price. On the other hand, class action lawsuits and an FDA Class I recall highlight product and...","category":"company","datetime":1783667522,"headline":"Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%"}, {"id":140859202,"url":"https://finnhub.io/api/news?id=58f1efd2e83e654f6121e6a1b04094f307caad61e61f28ca7e0ccc3d470db0fa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, adding another European market to its footprint. See our latest analysis for Insulet. Despite the positive headlines from Spain, Insulet’s share price return over the past year has declined 46.78% on a total shareholder return basis, with shorter term share price momentum also weaker. This suggests investors are still...","category":"company","datetime":1783664067,"headline":"Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?"}, {"id":140842034,"url":"https://finnhub.io/api/news?id=477733d09dcd2e121d533f3b049591b3144caf1158d9c71bbde4a4e183389799","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Insulet Corporation (NASDAQ:PODD) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares. The adjustment […]","category":"company","datetime":1783522238,"headline":"Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?"}, {"id":140833269,"url":"https://finnhub.io/api/news?id=c796ad28ea9e117479a6192602eaaf9d33661e5e3b2f8ea8e0092f07da6091c7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.","category":"company","datetime":1783440604,"headline":"Why Insulet (PODD) Could Beat Earnings Estimates Again"}, {"id":140823759,"url":"https://finnhub.io/api/news?id=70981f867abb7a5996d01df684428d6bc3615b134a9d79d89714e8e2d2d4687c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet Corporation (NASDAQ:PODD) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 23, Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation (NASDAQ:PODD) with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless […]","category":"company","datetime":1783367117,"headline":"Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target"}
raw_source {"id":141053264,"url":"https://finnhub.io/api/news?id=c6d4a617d1bdce4c9afd1e0af02dacba3cd4cf134beba65055396043f906e495","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"GE HealthCare (GEHC) delivered earnings and revenue surprises of +8.65% and +0.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785324604,"headline":"GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates"}, {"id":140986477,"url":"https://finnhub.io/api/news?id=f32f9a012b63e2f88ec53c995cc995cda84cbe064f7b767315ecd8744357c7a8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.","category":"company","datetime":1784724213,"headline":"Insulet's Q2 2026 Earnings: What to Expect"}, {"id":140962172,"url":"https://finnhub.io/api/news?id=44af7309e58675cb40be8aeeee3efff2cee0f08be150bf28a1d32be71de2341b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Last week’s chip-led selloff showcased just how quickly sentiment on AI can shift and drive a rotation out of tech stocks. Goldman Sachs outlined three investment themes to play for investors worried about AI overexposure in their portfolio.","category":"company","datetime":1784565813,"headline":"Goldman Flags 3 AI-Resistant Investment Themes to Watch"}, {"id":140959736,"url":"https://finnhub.io/api/news?id=a8230b43f95bd036aa6e7cd4d32ae1f9b2beee7fabc14fe8604858ec2cdbb8dc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.","category":"company","datetime":1784549733,"headline":"1 Healthcare Stock to Target This Week and 2 We Brush Off"}, {"id":140049019,"url":"https://finnhub.io/api/news?id=7a629db8b449d905f61c4ffdf1b6684b342fcc22ebf1c524d64b1d845debb6ed","image":"","source":"Benzinga","related":"PODD","summary":"","category":"company","datetime":1784205329,"headline":"Carlsmed Announces Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion Procedure"}, {"id":140917722,"url":"https://finnhub.io/api/news?id=e46a532cdcf0dfbb64292f767f3f6794a84ac828a31a539cbc29825883436c13","image":"https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp","source":"ChartMill","related":"PODD","summary":"Insulet Corp (PODD) fits the Affordable Growth strategy with strong earnings and revenue momentum, neutral valuation, and high profitability—offering compound growth potential without overpaying for the stock.","category":"company","datetime":1784190635,"headline":"Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum"}, {"id":140911175,"url":"https://finnhub.io/api/news?id=9ea669041b7b7a8adcc9db15934485b194ba72279e2d2187e204a134da4856a2","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2224008766/image_2224008766.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"PODD","summary":"Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Read more here.","category":"company","datetime":1784123760,"headline":"Artisan Mid Cap Fund Q2 2026 Performance Review"}, {"id":140907582,"url":"https://finnhub.io/api/news?id=3c2b31b362f1bdc3ff422a9746ec2e810ef39c6a13921670528d9866862f30e2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.","category":"company","datetime":1784112797,"headline":"3 Quality Compounders on Our Buy List"}, {"id":140906545,"url":"https://finnhub.io/api/news?id=53e347fb265ff938645e30e952d9271c2f45f7ed8a216d0659ff6229411ce739","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"PODD","summary":"AMD stock price exploded higher in the quarter as the evolution of the LLM market has led us to agentic AI workloads.","category":"company","datetime":1784091900,"headline":"The Ithaka Group Q2 2026 Portfolio Review"}, {"id":140894732,"url":"https://finnhub.io/api/news?id=ef7054d7fea5ab7ddbd44b257955e3e897687e5769a2f7cb8a97942908015958","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"ACTON, Mass., July 14, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech co","category":"company","datetime":1784012400,"headline":"Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss"}, {"id":140894196,"url":"https://finnhub.io/api/news?id=ce54dcd3213fe39a575ae9d8dfca8d8c3c8ab18a053b31d59baa95ee32ca2d22","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2025 and is expected to reach USD 18.3 Billion in 2026 and is expected to reach around USD 39.4 Billion by 2035, at a CAGR of 8.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Insulet Corporati","category":"company","datetime":1784003400,"headline":"Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights"}, {"id":140897566,"url":"https://finnhub.io/api/news?id=a5dd8b67da2fb5b2830eaf9d5dd09796e92ad6e1db6f2765b85b1c2f2c8bd7ea","image":"","source":"Benzinga","related":"PODD","summary":"The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep","category":"company","datetime":1783999615,"headline":"Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes"}, {"id":140886060,"url":"https://finnhub.io/api/news?id=f420465558bfb0230f65b0aa19dc7f11d45f18388c9c4b1a6a92b970aba5542a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]","category":"company","datetime":1783950597,"headline":"Insulet Corporation (PODD) Fell Along with Broad Medtech Sector"}, {"id":140886061,"url":"https://finnhub.io/api/news?id=004a2ffee3bcc377b85bd87bf51a2e55126b072fdea6a524e0a73b60b2f20163","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.","category":"company","datetime":1783945802,"headline":"Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago"}, {"id":140897567,"url":"https://finnhub.io/api/news?id=05394a86765144d80ce8c11f5a4d8c14a835fb3cbe9c0f88f3e9df011fefde0d","image":"","source":"Benzinga","related":"PODD","summary":"Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $219 to $210.","category":"company","datetime":1783945388,"headline":"Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210"}, {"id":140897568,"url":"https://finnhub.io/api/news?id=95d531ed28dc1fe0a6e4c2f4f5918f49fefbfa081d3b405c3eb13e2be633b930","image":"","source":"Benzinga","related":"PODD","summary":"RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $280 to $245.","category":"company","datetime":1783938004,"headline":"RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245"}, {"id":140861684,"url":"https://finnhub.io/api/news?id=2d80c78d867e1b8c4361f0f878b8dcf7d65ca471b42d1cd018154a011edfcc86","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.","category":"company","datetime":1783685317,"headline":"DXCM Grew. The Stock Did Not. Someone Is Wrong"}, {"id":140864663,"url":"https://finnhub.io/api/news?id=021ae588c494fe31948d77fd9d82b0b826141856a6d848e1ee1e508f63afb827","image":"","source":"Benzinga","related":"PODD","summary":"Stifel analyst Jonathan Block maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $225.","category":"company","datetime":1783674901,"headline":"Stifel Maintains Buy on Insulet, Lowers Price Target to $225"}, {"id":140859201,"url":"https://finnhub.io/api/news?id=414b0a5634543092ba8bf64f081fcb337e447dd1b8872829ff817b395e428636","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet stock has fallen sharply over the past year, yet the valuation checks still lean toward the shares being on the expensive side rather than a clear bargain. Insulet is down 46.8% over the past year, which means anyone looking at the stock today is doing so after a significant reset in the share price. On the one hand, growth expectations around the Omnipod franchise may support the current price. On the other hand, class action lawsuits and an FDA Class I recall highlight product and...","category":"company","datetime":1783667522,"headline":"Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%"}, {"id":140859202,"url":"https://finnhub.io/api/news?id=58f1efd2e83e654f6121e6a1b04094f307caad61e61f28ca7e0ccc3d470db0fa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, adding another European market to its footprint. See our latest analysis for Insulet. Despite the positive headlines from Spain, Insulet’s share price return over the past year has declined 46.78% on a total shareholder return basis, with shorter term share price momentum also weaker. This suggests investors are still...","category":"company","datetime":1783664067,"headline":"Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?"}, {"id":140845618,"url":"https://finnhub.io/api/news?id=a88f675a10eacf733ae13992621b5bb45942e9915886ecb5c472a50a1e8262a8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.","category":"company","datetime":1783546694,"headline":"Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM"}, {"id":140842034,"url":"https://finnhub.io/api/news?id=477733d09dcd2e121d533f3b049591b3144caf1158d9c71bbde4a4e183389799","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Insulet Corporation (NASDAQ:PODD) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares. The adjustment […]","category":"company","datetime":1783522238,"headline":"Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?"}, {"id":140841995,"url":"https://finnhub.io/api/news?id=2a9b52f2da4b5a22c4f058f2630f217896981d69db9faf8e3d076c2ef6f7a72e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"PODD expands Omnipod 5 to Spain, marking its 20th country launch and adding Omnipod Discover to strengthen digital diabetes care.","category":"company","datetime":1783520460,"headline":"Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain"}, {"id":140854503,"url":"https://finnhub.io/api/news?id=3e088629164dc7360d68d656ec8488dac831c805d2116899645d739f5927ab42","image":"","source":"Benzinga","related":"PODD","summary":"Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $165 to $172.","category":"company","datetime":1783510607,"headline":"Citigroup Maintains Neutral on Insulet, Raises Price Target to $172"}, {"id":140833268,"url":"https://finnhub.io/api/news?id=cfbab5ac2b530f4ed8b5827bb5a95dee15dab8e9fd83e5b4fb8728afdbf71d52","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.","category":"company","datetime":1783441440,"headline":"Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?"}, {"id":140833269,"url":"https://finnhub.io/api/news?id=c796ad28ea9e117479a6192602eaaf9d33661e5e3b2f8ea8e0092f07da6091c7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.","category":"company","datetime":1783440604,"headline":"Why Insulet (PODD) Could Beat Earnings Estimates Again"}, {"id":140830065,"url":"https://finnhub.io/api/news?id=3c61c162eeb4a4ff55bbbf7eb416d76bd56a1411992abae065eed559761e61eb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.","category":"company","datetime":1783430548,"headline":"How To Target A 10% Yield While Catching The BSX Stock Knife?"}, {"id":140831550,"url":"https://finnhub.io/api/news?id=38d7ab3fc039fe2662f7a8274ac87455747d9c60b1ef8d0e4d601c6ce6396dbf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.","category":"company","datetime":1783422600,"headline":"Insulet launches Omnipod 5 in Spain"}, {"id":140823759,"url":"https://finnhub.io/api/news?id=70981f867abb7a5996d01df684428d6bc3615b134a9d79d89714e8e2d2d4687c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"Insulet Corporation (NASDAQ:PODD) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 23, Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation (NASDAQ:PODD) with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless […]","category":"company","datetime":1783367117,"headline":"Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target"}, {"id":140820483,"url":"https://finnhub.io/api/news?id=94fc5e1555bc065d9d774254f722bc9d84522a9c3c15d091f554e0694959ee94","image":"https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp","source":"ChartMill","related":"PODD","summary":"Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Monday and stay ahead of the market trends.","category":"company","datetime":1783348501,"headline":"Which S&P500 stocks are gapping on Monday?"}, {"id":140824852,"url":"https://finnhub.io/api/news?id=e9fcc42b04affbd149c40d06670b7e18026902c7418c31794f540d47a4db1ac5","image":"https://cdn.benzinga.com/files/images/story/2026/07/06/Insulet-Omnipod5-Diabetes.png?width=2048&height=1536","source":"Benzinga","related":"PODD","summary":"FDA classified Insulet's Omnipod pod recall as Class I after reports of insulin under-delivery linked to 24 serious injuries.","category":"company","datetime":1783345007,"headline":"FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports"}, {"id":140824853,"url":"https://finnhub.io/api/news?id=978ec44776a2a0f805247edd99be063c26ff16978b4a66c132609524213d0b86","image":"","source":"Benzinga","related":"PODD","summary":"Evercore ISI Group analyst Daniel Markowitz maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $180.","category":"company","datetime":1783342437,"headline":"Evercore ISI Group Maintains Outperform on Insulet, Lowers Price Target to $180"}, {"id":140819264,"url":"https://finnhub.io/api/news?id=544e132a13bd7a9e08a0f6ba63e1a9a9ab0a515999208bd55f95ce2512acc7d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"PODD","summary":"ACTON, Mass., July 06, 2026--Insulet Accelerates Global Growth with Launch of Omnipod 5 and Omnipod Discover in Spain, Expanding Access to Tubeless Diabetes Technology","category":"company","datetime":1783335600,"headline":"Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology"}, {"id":140824854,"url":"https://finnhub.io/api/news?id=aba5f3cb57a5a04c670553cb57055c7431df0d5c21a6bc3ae586b72d98199a5a","image":"","source":"Benzinga","related":"PODD","summary":"Spain is the 26th country where Insulet sells Omnipod, and the 20th country where Omnipod 5 is available, further accelerating Insulet’s mission to transform the lives of people with diabetes around the world.","category":"company","datetime":1783322174,"headline":"Insulet Launches Its Omnipod 5 Automated Insulin Delivery And Proprietary Data Management System Omnipod Discover In Spain"}
data_source finnhub_news_keyword_model
article_count 7
negative_hits 0
positive_hits 5
recomputed_at_score true
sentiment_score_raw 1.7
source_article_count 34
discarded_article_count 27
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.2 5/110 64% 3.2
資金流 13.2 20/110 66% 13.2
市場環境 5.8 15/110 38.67% 5.8
催化劑 2 20/110 10% 2
風險管理 6.1 10/110 61% 6.1
技術信號 24.2 30/110 80.67% 24.2
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 6/50
ret_5d 0.0285
max_score 50
max_total 50
raw_total 6
vcp_bonus 0
vol_ratio 1.109
ret_points 4
vol_points 2
range_ratio 0.8905
volat_points 0
day_range_pct 0.0321
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 0
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Elevated
reason risk management score >= 5/10

position

score 1.1

details

atrPct 3.9504
turnoverUsdM 238.9381
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.8

stopLevels

symbol US.PODD
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 156.2922

strength_details

ma_score 1.5
atr_score 1
rsi_score 3
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.6
stop_loss_percent 7.9
take_profit_price 191.3313
target_multiplier 2.2
technical_strength 2.2
take_profit_percent 12.7
positionPoints 1.1
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.6074
stopLossPercent 7.9009
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.2/5分
資金流分析總分: 13.2/20分
市場環境分析總分: 5.8/15分
催化劑分析: 2/20分
風險管理總分: 6.1/10分
技術信號分析總分: 24.2/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 6.7039
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.95
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 134.37
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0467
kdj
d 61.68
j 73.14
k 65.5
rule Cursor_18.24 K/D cross
score 6
signal 強金叉
mfi
rule Cursor_18.24 MFI bands
level 入貨中
score 8
value 65.93
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 6
trend 有流入
value 8262403
recentSlope 104650.3
previousSlope 243230
rsi
value 63.28
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 161.5744
position SAR喺價下
distancePct 4.79
previousTrend 上升
ma50
value 155.5868
macd
macd 3.2595
trend 強烈看漲
signal 2.9897
histogram 0.2698
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 163.1122
position 連續5日>VWAP
consecutiveAbove 7
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.11
score 6
avgVolume 1271450
currentVolume 1408003
derived
ma20 163.1505
ma50 155.5868
prevClose 165.35
avgVolume10 1228500
avgVolume20 1271450
changePercent 2.63
avgVolumeForScore 1271450
ma_cross
ma20 163.1505
ma50 155.5868
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 162.654
prevMa50 155.3246
spreadPct 4.86
isVolumeBreakout false
bollinger
lower 155.5655
upper 170.7355
position 上半部
rsi_short
value 68.96
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.11

Raw calculation JSON

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.9504419563936364,
        "turnoverUsdM": 238.9381091,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.PODD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 156.2922,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.6,
      "stop_loss_percent": 7.9,
      "take_profit_price": 191.3313,
      "target_multiplier": 2.2,
      "technical_strength": 2.2,
      "take_profit_percent": 12.7
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.6074150867405537,
    "stopLossPercent": 7.900883912787273,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 66.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 6
  },
  "market": {
    "ma20": 163.1505,
    "ma50": 155.5868,
    "close": 169.7,
    "prevClose": 165.35,
    "avgVolume20": 1271450,
    "volumeRatio": 1.11,
    "changePercent": 2.63
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 6,
    "details": {
      "ret_5d": 0.028484848484848335,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 6,
      "vcp_bonus": 0,
      "vol_ratio": 1.1090261778455164,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 0.8904767072096359,
      "volat_points": 0,
      "day_range_pct": 0.03211549793753676,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 66.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 5.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 38.67,
        "contribution": 5.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.1,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 61,
        "contribution": 6.1
      },
      {
        "raw": 24.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 80.67,
        "contribution": 24.2
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 60.5,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 5.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.1/10分",
      "技術信號分析總分: 24.2/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.2,
      "資金流": 13.2,
      "市場環境": 5.8,
      "情緒分析": 6,
      "技術信號": 24.2,
      "風險管理": 6.1
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 238.9381091,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.PODD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 699.88099675,
                "ma50": 714.8264005399999,
                "name": "QQQ",
                "close": 700.070007,
                "points": 1
              },
              "spy": {
                "ma20": 746.0140036500002,
                "ma50": 745.31840316,
                "name": "SPY",
                "close": 757.66998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.9504419563936364,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 0,
              "positiveHits": 5,
              "sentimentScoreRaw": 1.7
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140917722,
                "url": "https://finnhub.io/api/news?id=e46a532cdcf0dfbb64292f767f3f6794a84ac828a31a539cbc29825883436c13",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "PODD",
                "summary": "Insulet Corp (PODD) fits the Affordable Growth strategy with strong earnings and revenue momentum, neutral valuation, and high profitability—offering compound growth potential without overpaying for the stock.",
                "category": "company",
                "datetime": 1784190635,
                "headline": "Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum"
              },
              {
                "id": 140886060,
                "url": "https://finnhub.io/api/news?id=f420465558bfb0230f65b0aa19dc7f11d45f18388c9c4b1a6a92b970aba5542a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]",
                "category": "company",
                "datetime": 1783950597,
                "headline": "Insulet Corporation (PODD) Fell Along with Broad Medtech Sector"
              },
              {
                "id": 140859201,
                "url": "https://finnhub.io/api/news?id=414b0a5634543092ba8bf64f081fcb337e447dd1b8872829ff817b395e428636",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet stock has fallen sharply over the past year, yet the valuation checks still lean toward the shares being on the expensive side rather than a clear bargain. Insulet is down 46.8% over the past year, which means anyone looking at the stock today is doing so after a significant reset in the share price. On the one hand, growth expectations around the Omnipod franchise may support the current price. On the other hand, class action lawsuits and an FDA Class I recall highlight product and...",
                "category": "company",
                "datetime": 1783667522,
                "headline": "Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%"
              },
              {
                "id": 140859202,
                "url": "https://finnhub.io/api/news?id=58f1efd2e83e654f6121e6a1b04094f307caad61e61f28ca7e0ccc3d470db0fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, adding another European market to its footprint. See our latest analysis for Insulet. Despite the positive headlines from Spain, Insulet’s share price return over the past year has declined 46.78% on a total shareholder return basis, with shorter term share price momentum also weaker. This suggests investors are still...",
                "category": "company",
                "datetime": 1783664067,
                "headline": "Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?"
              },
              {
                "id": 140842034,
                "url": "https://finnhub.io/api/news?id=477733d09dcd2e121d533f3b049591b3144caf1158d9c71bbde4a4e183389799",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Insulet Corporation (NASDAQ:PODD) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares. The adjustment […]",
                "category": "company",
                "datetime": 1783522238,
                "headline": "Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?"
              },
              {
                "id": 140833269,
                "url": "https://finnhub.io/api/news?id=c796ad28ea9e117479a6192602eaaf9d33661e5e3b2f8ea8e0092f07da6091c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440604,
                "headline": "Why Insulet (PODD) Could Beat Earnings Estimates Again"
              },
              {
                "id": 140823759,
                "url": "https://finnhub.io/api/news?id=70981f867abb7a5996d01df684428d6bc3615b134a9d79d89714e8e2d2d4687c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet Corporation (NASDAQ:PODD) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 23, Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation (NASDAQ:PODD) with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless […]",
                "category": "company",
                "datetime": 1783367117,
                "headline": "Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target"
              }
            ],
            "raw_source": [
              {
                "id": 141053264,
                "url": "https://finnhub.io/api/news?id=c6d4a617d1bdce4c9afd1e0af02dacba3cd4cf134beba65055396043f906e495",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "GE HealthCare (GEHC) delivered earnings and revenue surprises of +8.65% and +0.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785324604,
                "headline": "GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 140986477,
                "url": "https://finnhub.io/api/news?id=f32f9a012b63e2f88ec53c995cc995cda84cbe064f7b767315ecd8744357c7a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
                "category": "company",
                "datetime": 1784724213,
                "headline": "Insulet's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140962172,
                "url": "https://finnhub.io/api/news?id=44af7309e58675cb40be8aeeee3efff2cee0f08be150bf28a1d32be71de2341b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Last week’s chip-led selloff showcased just how quickly sentiment on AI can shift and drive a rotation out of tech stocks. Goldman Sachs outlined three investment themes to play for investors worried about AI overexposure in their portfolio.",
                "category": "company",
                "datetime": 1784565813,
                "headline": "Goldman Flags 3 AI-Resistant Investment Themes to Watch"
              },
              {
                "id": 140959736,
                "url": "https://finnhub.io/api/news?id=a8230b43f95bd036aa6e7cd4d32ae1f9b2beee7fabc14fe8604858ec2cdbb8dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.",
                "category": "company",
                "datetime": 1784549733,
                "headline": "1 Healthcare Stock to Target This Week and 2 We Brush Off"
              },
              {
                "id": 140049019,
                "url": "https://finnhub.io/api/news?id=7a629db8b449d905f61c4ffdf1b6684b342fcc22ebf1c524d64b1d845debb6ed",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "",
                "category": "company",
                "datetime": 1784205329,
                "headline": "Carlsmed Announces Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion Procedure"
              },
              {
                "id": 140917722,
                "url": "https://finnhub.io/api/news?id=e46a532cdcf0dfbb64292f767f3f6794a84ac828a31a539cbc29825883436c13",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "PODD",
                "summary": "Insulet Corp (PODD) fits the Affordable Growth strategy with strong earnings and revenue momentum, neutral valuation, and high profitability—offering compound growth potential without overpaying for the stock.",
                "category": "company",
                "datetime": 1784190635,
                "headline": "Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum"
              },
              {
                "id": 140911175,
                "url": "https://finnhub.io/api/news?id=9ea669041b7b7a8adcc9db15934485b194ba72279e2d2187e204a134da4856a2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2224008766/image_2224008766.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PODD",
                "summary": "Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Read more here.",
                "category": "company",
                "datetime": 1784123760,
                "headline": "Artisan Mid Cap Fund Q2 2026 Performance Review"
              },
              {
                "id": 140907582,
                "url": "https://finnhub.io/api/news?id=3c2b31b362f1bdc3ff422a9746ec2e810ef39c6a13921670528d9866862f30e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.",
                "category": "company",
                "datetime": 1784112797,
                "headline": "3 Quality Compounders on Our Buy List"
              },
              {
                "id": 140906545,
                "url": "https://finnhub.io/api/news?id=53e347fb265ff938645e30e952d9271c2f45f7ed8a216d0659ff6229411ce739",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PODD",
                "summary": "AMD stock price exploded higher in the quarter as the evolution of the LLM market has led us to agentic AI workloads.",
                "category": "company",
                "datetime": 1784091900,
                "headline": "The Ithaka Group Q2 2026 Portfolio Review"
              },
              {
                "id": 140894732,
                "url": "https://finnhub.io/api/news?id=ef7054d7fea5ab7ddbd44b257955e3e897687e5769a2f7cb8a97942908015958",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "ACTON, Mass., July 14, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech co",
                "category": "company",
                "datetime": 1784012400,
                "headline": "Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss"
              },
              {
                "id": 140894196,
                "url": "https://finnhub.io/api/news?id=ce54dcd3213fe39a575ae9d8dfca8d8c3c8ab18a053b31d59baa95ee32ca2d22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2025 and is expected to reach USD 18.3 Billion in 2026 and is expected to reach around USD 39.4 Billion by 2035, at a CAGR of 8.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Insulet Corporati",
                "category": "company",
                "datetime": 1784003400,
                "headline": "Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights"
              },
              {
                "id": 140897566,
                "url": "https://finnhub.io/api/news?id=a5dd8b67da2fb5b2830eaf9d5dd09796e92ad6e1db6f2765b85b1c2f2c8bd7ea",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep",
                "category": "company",
                "datetime": 1783999615,
                "headline": "Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes"
              },
              {
                "id": 140886060,
                "url": "https://finnhub.io/api/news?id=f420465558bfb0230f65b0aa19dc7f11d45f18388c9c4b1a6a92b970aba5542a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]",
                "category": "company",
                "datetime": 1783950597,
                "headline": "Insulet Corporation (PODD) Fell Along with Broad Medtech Sector"
              },
              {
                "id": 140886061,
                "url": "https://finnhub.io/api/news?id=004a2ffee3bcc377b85bd87bf51a2e55126b072fdea6a524e0a73b60b2f20163",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1783945802,
                "headline": "Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago"
              },
              {
                "id": 140897567,
                "url": "https://finnhub.io/api/news?id=05394a86765144d80ce8c11f5a4d8c14a835fb3cbe9c0f88f3e9df011fefde0d",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "Truist Securities  analyst Richard Newitter   maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $219 to $210.",
                "category": "company",
                "datetime": 1783945388,
                "headline": "Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210"
              },
              {
                "id": 140897568,
                "url": "https://finnhub.io/api/news?id=95d531ed28dc1fe0a6e4c2f4f5918f49fefbfa081d3b405c3eb13e2be633b930",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "RBC Capital  analyst Shagun Singh   maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $280 to $245.",
                "category": "company",
                "datetime": 1783938004,
                "headline": "RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245"
              },
              {
                "id": 140861684,
                "url": "https://finnhub.io/api/news?id=2d80c78d867e1b8c4361f0f878b8dcf7d65ca471b42d1cd018154a011edfcc86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.",
                "category": "company",
                "datetime": 1783685317,
                "headline": "DXCM Grew. The Stock Did Not. Someone Is Wrong"
              },
              {
                "id": 140864663,
                "url": "https://finnhub.io/api/news?id=021ae588c494fe31948d77fd9d82b0b826141856a6d848e1ee1e508f63afb827",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "Stifel  analyst Jonathan Block   maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $225.",
                "category": "company",
                "datetime": 1783674901,
                "headline": "Stifel Maintains Buy on Insulet, Lowers Price Target to $225"
              },
              {
                "id": 140859201,
                "url": "https://finnhub.io/api/news?id=414b0a5634543092ba8bf64f081fcb337e447dd1b8872829ff817b395e428636",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet stock has fallen sharply over the past year, yet the valuation checks still lean toward the shares being on the expensive side rather than a clear bargain. Insulet is down 46.8% over the past year, which means anyone looking at the stock today is doing so after a significant reset in the share price. On the one hand, growth expectations around the Omnipod franchise may support the current price. On the other hand, class action lawsuits and an FDA Class I recall highlight product and...",
                "category": "company",
                "datetime": 1783667522,
                "headline": "Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%"
              },
              {
                "id": 140859202,
                "url": "https://finnhub.io/api/news?id=58f1efd2e83e654f6121e6a1b04094f307caad61e61f28ca7e0ccc3d470db0fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, adding another European market to its footprint. See our latest analysis for Insulet. Despite the positive headlines from Spain, Insulet’s share price return over the past year has declined 46.78% on a total shareholder return basis, with shorter term share price momentum also weaker. This suggests investors are still...",
                "category": "company",
                "datetime": 1783664067,
                "headline": "Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?"
              },
              {
                "id": 140845618,
                "url": "https://finnhub.io/api/news?id=a88f675a10eacf733ae13992621b5bb45942e9915886ecb5c472a50a1e8262a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1783546694,
                "headline": "Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM"
              },
              {
                "id": 140842034,
                "url": "https://finnhub.io/api/news?id=477733d09dcd2e121d533f3b049591b3144caf1158d9c71bbde4a4e183389799",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Insulet Corporation (NASDAQ:PODD) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares. The adjustment […]",
                "category": "company",
                "datetime": 1783522238,
                "headline": "Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?"
              },
              {
                "id": 140841995,
                "url": "https://finnhub.io/api/news?id=2a9b52f2da4b5a22c4f058f2630f217896981d69db9faf8e3d076c2ef6f7a72e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "PODD expands Omnipod 5 to Spain, marking its 20th country launch and adding Omnipod Discover to strengthen digital diabetes care.",
                "category": "company",
                "datetime": 1783520460,
                "headline": "Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain"
              },
              {
                "id": 140854503,
                "url": "https://finnhub.io/api/news?id=3e088629164dc7360d68d656ec8488dac831c805d2116899645d739f5927ab42",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $165 to $172.",
                "category": "company",
                "datetime": 1783510607,
                "headline": "Citigroup Maintains Neutral on Insulet, Raises Price Target to $172"
              },
              {
                "id": 140833268,
                "url": "https://finnhub.io/api/news?id=cfbab5ac2b530f4ed8b5827bb5a95dee15dab8e9fd83e5b4fb8728afdbf71d52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.",
                "category": "company",
                "datetime": 1783441440,
                "headline": "Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?"
              },
              {
                "id": 140833269,
                "url": "https://finnhub.io/api/news?id=c796ad28ea9e117479a6192602eaaf9d33661e5e3b2f8ea8e0092f07da6091c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440604,
                "headline": "Why Insulet (PODD) Could Beat Earnings Estimates Again"
              },
              {
                "id": 140830065,
                "url": "https://finnhub.io/api/news?id=3c61c162eeb4a4ff55bbbf7eb416d76bd56a1411992abae065eed559761e61eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.",
                "category": "company",
                "datetime": 1783430548,
                "headline": "How To Target A 10% Yield While Catching The BSX Stock Knife?"
              },
              {
                "id": 140831550,
                "url": "https://finnhub.io/api/news?id=38d7ab3fc039fe2662f7a8274ac87455747d9c60b1ef8d0e4d601c6ce6396dbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.",
                "category": "company",
                "datetime": 1783422600,
                "headline": "Insulet launches Omnipod 5 in Spain"
              },
              {
                "id": 140823759,
                "url": "https://finnhub.io/api/news?id=70981f867abb7a5996d01df684428d6bc3615b134a9d79d89714e8e2d2d4687c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "Insulet Corporation (NASDAQ:PODD) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 23, Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation (NASDAQ:PODD) with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless […]",
                "category": "company",
                "datetime": 1783367117,
                "headline": "Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target"
              },
              {
                "id": 140820483,
                "url": "https://finnhub.io/api/news?id=94fc5e1555bc065d9d774254f722bc9d84522a9c3c15d091f554e0694959ee94",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "PODD",
                "summary": "Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Monday and stay ahead of the market trends.",
                "category": "company",
                "datetime": 1783348501,
                "headline": "Which S&P500 stocks are gapping on Monday?"
              },
              {
                "id": 140824852,
                "url": "https://finnhub.io/api/news?id=e9fcc42b04affbd149c40d06670b7e18026902c7418c31794f540d47a4db1ac5",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Insulet-Omnipod5-Diabetes.png?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "FDA classified Insulet's Omnipod pod recall as Class I after reports of insulin under-delivery linked to 24 serious injuries.",
                "category": "company",
                "datetime": 1783345007,
                "headline": "FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports"
              },
              {
                "id": 140824853,
                "url": "https://finnhub.io/api/news?id=978ec44776a2a0f805247edd99be063c26ff16978b4a66c132609524213d0b86",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "Evercore ISI Group  analyst Daniel Markowitz   maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $180.",
                "category": "company",
                "datetime": 1783342437,
                "headline": "Evercore ISI Group Maintains Outperform on Insulet, Lowers Price Target to $180"
              },
              {
                "id": 140819264,
                "url": "https://finnhub.io/api/news?id=544e132a13bd7a9e08a0f6ba63e1a9a9ab0a515999208bd55f95ce2512acc7d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PODD",
                "summary": "ACTON, Mass., July 06, 2026--Insulet Accelerates Global Growth with Launch of Omnipod 5 and Omnipod Discover in Spain, Expanding Access to Tubeless Diabetes Technology",
                "category": "company",
                "datetime": 1783335600,
                "headline": "Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology"
              },
              {
                "id": 140824854,
                "url": "https://finnhub.io/api/news?id=aba5f3cb57a5a04c670553cb57055c7431df0d5c21a6bc3ae586b72d98199a5a",
                "image": "",
                "source": "Benzinga",
                "related": "PODD",
                "summary": "Spain is the 26th country where Insulet sells Omnipod, and the 20th country where Omnipod 5 is available, further accelerating Insulet’s mission to transform the lives of people with diabetes around the world.",
                "category": "company",
                "datetime": 1783322174,
                "headline": "Insulet Launches Its Omnipod 5 Automated Insulin Delivery And Proprietary Data Management System Omnipod Discover In Spain"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 0,
            "positive_hits": 5,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.7,
            "source_article_count": 34,
            "discarded_article_count": 27
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 24.2,
        "grade": "優秀",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(20.1%→9.1%);跌縮量(近10日5日);站上MA50;Ready=Y;Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1455786.6666666667,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1252980,
              "avg_vol_20": 1269585,
              "avg_vol_30": 1455786.6666666667,
              "range_pct_10": 0.09121979964643483,
              "range_pct_20": 0.11868002357100758,
              "range_pct_30": 0.20111968179139658,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8606892951348183,
              "dist_to_20d_high": 0.01862132778163312,
              "down_shrink_days": 5,
              "breakout_level_20d": 172.92,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4535597850689171
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.9504419563936364,
              "turnoverUsdM": 238.9381091,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.PODD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 156.2922,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.6,
            "stop_loss_percent": 7.9,
            "take_profit_price": 191.3313,
            "target_multiplier": 2.2,
            "technical_strength": 2.2,
            "take_profit_percent": 12.7
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.6074150867405537,
          "stopLossPercent": 7.900883912787273,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.PODD",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 6.7039,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.95
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 134.37
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0467
    },
    "kdj": {
      "d": 61.68,
      "j": 73.14,
      "k": 65.5,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 65.93
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 8262403,
      "recentSlope": 104650.3,
      "previousSlope": 243230
    },
    "rsi": 63.28,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 161.5744,
      "position": "SAR喺價下",
      "distancePct": 4.79,
      "previousTrend": "上升"
    },
    "ma50": 155.5868,
    "macd": {
      "macd": 3.2595310976362555,
      "trend": "強烈看漲",
      "signal": 2.9897282845948308,
      "histogram": 0.2698028130414247
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 163.1122,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 7
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.11,
      "score": 6,
      "avgVolume": 1271450,
      "currentVolume": 1408003
    },
    "derived": {
      "ma20": 163.1505,
      "ma50": 155.5868,
      "prevClose": 165.35,
      "avgVolume10": 1228500,
      "avgVolume20": 1271450,
      "changePercent": 2.63,
      "avgVolumeForScore": 1271450
    },
    "ma_cross": {
      "ma20": 163.1505,
      "ma50": 155.5868,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 162.654,
      "prevMa50": 155.3246,
      "spreadPct": 4.86,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 155.5655,
      "upper": 170.7355,
      "position": "上半部"
    },
    "rsi_short": 68.96,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.11
    }
  }
}

Raw metrics JSON

{
  "close": 169.7,
  "volume": 1408003,
  "changePercent": 2.63
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.